drugset / Trial / NCT03378102

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

NCT03378102 ↗

Phase 0 Recruiting 20 enrolled Mari Dallas
NaSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxicities of adoptive T cell therapy. Adoptive T cell therapy is an investigational (experimental) therapy that works by using the blood of a donor that has immunity against the virus. The donor cells are collected and then the cells, called T cells, that are capable of defending against the virus are selected out. These selected T cells are then infused back into the patient, to try to give the immune system the ability to fight the infection. Adoptive T cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).

Timeline

Start
2019-01-04
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IFN-gamma-secreting HAdV antigen specific T cells Cell therapy 1000 cells/kg —
Subject IFN-gamma-secreting HAdV antigen specific T cells Cell therapy 200000 cells/kg —